Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Vuocolo

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.
Pageof 4